Literature DB >> 23551977

C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality.

J Fang1, P Nurden, P North, A T Nurden, L M Du, N Valentin, D A Wilcox.   

Abstract

BACKGROUND AND OBJECTIVES: β(3)-Deficient megakaryocytes were modified by human β(3)-lentivirus transduction and transplantation to express sufficient levels of a C560Rβ(3) amino acid substitution, for investigation of how an activated αII b β(3) conformation affects platelets in vivo in mice. PATIENT/
METHODS: As in our previous report of an R560β(3) mutation in a patient with Glanzmann thrombasthenia, R560β(3) murine platelets spontaneously bound antibody that only recognizes activated αII b β3 bound to its ligand, fibrinogen.
RESULTS: With this murine model, we showed that αII b -R560β3 mutation-mediated continuous binding of fibrinogen occurred in the absence of P-selectin surface expression, indicating that the integrin was in an active conformation, although the platelets circulated in a quiescent manner. Remarkably, only 35% of R560β(3) 'mutant' mice survived for 6 months after transplantation, whereas 87% of C560β(3) 'wild-type' mice remained alive. Pathologic examination revealed that R560β(3) mice had enlarged spleens with extramedullary hematopoiesis and increased hemosiderin, indicating hemorrhage. R560β(3) megakaryocytes and platelets showed abnormal morphology and irregular granule distribution. Interestingly, R560β(3) washed platelets could aggregate upon simultaneous addition of fibrinogen and physiologic agonists, but aggregation failed when platelets were exposed to fibrinogen before activation in vitro and in vivo.
CONCLUSIONS: The results demonstrate that continuous occupancy of αIIb β3 with fibrinogen disrupts platelet structure and function, leading to hemorrhagic death consistent with Glanzmann thrombasthenia rather than a thrombotic state.
© 2013 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  glanzmann thrombasthenia; hematopoietic stem cells; integrin αIIbβ3; lentivirus gene transfer; megakaryocytes; platelets

Mesh:

Substances:

Year:  2013        PMID: 23551977      PMCID: PMC3702628          DOI: 10.1111/jth.12209

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  27 in total

1.  A defect of platelet aggregation associated with an abnormal distribution of glycoprotein IIb-IIIa complexes within the platelet: the cause of a lifelong bleeding disorder.

Authors:  R Hardisty; D Pidard; A Cox; T Nokes; C Legrand; C Bouillot; A Pannocchia; E Heilmann; P Hourdillé; S Bellucci
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

2.  Emperipolesis of granulocytes within megakaryocytes.

Authors:  A de Pasquale; P Paterlini; D Quaglino; D Quaglino
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

3.  Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia.

Authors:  J Ruan; M Schmugge; K J Clemetson; E Cazes; R Combrie; F Bourre; A T Nurden
Journal:  Br J Haematol       Date:  1999-05       Impact factor: 6.998

4.  Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia.

Authors:  Juan Fang; Kairbaan Hodivala-Dilke; Bryon D Johnson; Lily M Du; Richard O Hynes; Gilbert C White; David A Wilcox
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

5.  Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients.

Authors:  H Ambo; T Kamata; M Handa; M Taki; M Kuwajima; Y Kawai; A Oda; M Murata; Y Takada; K Watanabe; Y Ikeda
Journal:  Biochem Biophys Res Commun       Date:  1998-10-29       Impact factor: 3.575

6.  R to Q amino acid substitution in the GFFKR sequence of the cytoplasmic domain of the integrin IIb subunit in a patient with a Glanzmann's thrombasthenia-like syndrome.

Authors:  O Peyruchaud; A T Nurden; S Milet; L Macchi; A Pannochia; P F Bray; N Kieffer; F Bourre
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

7.  Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII.

Authors:  D A Wilcox; Q Shi; P Nurden; S L Haberichter; J B Rosenberg; B D Johnson; A T Nurden; G C White; R R Montgomery
Journal:  J Thromb Haemost       Date:  2003-12       Impact factor: 5.824

8.  Emperipolesis of neutrophils by dysmorphic megakaryocytes.

Authors:  R T Parmley; T H Kim; R L Austin; C S Alvarado; A H Ragab
Journal:  Am J Hematol       Date:  1982-12       Impact factor: 10.047

9.  Two different beta3 cysteine substitutions alter alphaIIb beta3 maturation and result in Glanzmann thrombasthenia.

Authors:  S Milet-Marsal; C Breillat; O Peyruchaud; P Nurden; R Combrié; A Nurden; F Bourre
Journal:  Thromb Haemost       Date:  2002-07       Impact factor: 5.249

10.  Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival.

Authors:  K M Hodivala-Dilke; K P McHugh; D A Tsakiris; H Rayburn; D Crowley; M Ullman-Culleré; F P Ross; B S Coller; S Teitelbaum; R O Hynes
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more
  10 in total

1.  Internal relationship between symptomatic venous thromboembolism and risk factors: up-regulation of integrin β1, β2 and β3 levels.

Authors:  Qianglin Duan; Lemin Wang; Fan Yang; Jue Li; Yanli Song; Zhu Gong; Guiyuan Li; Haoming Song; Xiaoyu Zhang; Zugang Shen; Anthony Dart
Journal:  Am J Transl Res       Date:  2015-03-15       Impact factor: 4.060

2.  Activation of circulated immune cells and inflammatory immune adherence are involved in the whole process of acute venous thrombosis.

Authors:  Le-Min Wang; Qiang-Lin Duan; Fan Yang; Xiang-Hua Yi; Yu Zeng; Hong-Yan Tian; Wei Lv; Yun Jin
Journal:  Int J Clin Exp Med       Date:  2014-03-15

Review 3.  The role of Nox-mediated oxidation in the regulation of cytoskeletal dynamics.

Authors:  Alejandra Valdivia; Charity Duran; Alejandra San Martin
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Increased expressions of integrin subunit β1, β2 and β3 in patients with venous thromboembolism: new markers for venous thromboembolism.

Authors:  Yanli Song; Fan Yang; Lemin Wang; Qianglin Duan; Yun Jin; Zhu Gong
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 5.  Glanzmann thrombasthenia: state of the art and future directions.

Authors:  Alan T Nurden; Xavier Pillois; David A Wilcox
Journal:  Semin Thromb Hemost       Date:  2013-08-08       Impact factor: 4.180

6.  Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606.

Authors:  Kendra H Oliver; Tammy Jessen; Emily L Crawford; Chang Y Chung; James S Sutcliffe; Ana M Carneiro
Journal:  Mol Pharmacol       Date:  2014-04-02       Impact factor: 4.436

7.  Glanzmann thrombasthenia in Pakistan: molecular analysis and identification of novel mutations.

Authors:  A Haghighi; M Borhany; A Ghazi; N Edwards; A Tabaksert; A Haghighi; N Fatima; T S Shamsi; J A Sayer
Journal:  Clin Genet       Date:  2015-07-15       Impact factor: 4.438

8.  Genetic classification and confirmation of inherited platelet disorders: current status in Korea.

Authors:  Ye Jee Shim
Journal:  Clin Exp Pediatr       Date:  2020-02-06

Review 9.  Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.

Authors:  Øystein Bruserud; Håkon Reikvam; Annette Katharina Brenner
Journal:  Molecules       Date:  2022-01-23       Impact factor: 4.411

Review 10.  Inherited platelet disorders: toward DNA-based diagnosis.

Authors:  Claire Lentaigne; Kathleen Freson; Michael A Laffan; Ernest Turro; Willem H Ouwehand
Journal:  Blood       Date:  2016-04-19       Impact factor: 25.476

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.